|
1) Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008; 7: 538-47
|
|
|
|
2) Rose JW, Foley JF, Carlson NG. Monoclonal antibody treatments for multiple sclerosis. Curr Treat Options Neurol. 2009; 11: 211-20
|
|
|
|
|
|
3) Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005; 64: 1336-42
|
|
|
|
|
|
4) Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003; 348: 24-32
|
|
|
|
|
|
5) Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354: 899-910
|
|
|
|
|
|
6) Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354: 911-23
|
|
|
|
|
|
7) Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 2008; 358: 647-8
|
|
|
|
|
|
8) Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapse-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009; 8: 254-60
|
|
|
|
|
|
9) Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358: 676-88
|
|
|
|
|
|
10) Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008; 63: 395-400
|
|
|
|
|
|
11) Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6: 805-15
|
|
|
|
|
|
12) Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47: 707-17
|
|
|
|
|
|
13) Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64: 1270-2
|
|
|
|
|
|
14) Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65: 1443-8
|
|
|
|
|
|
15) Rai KR. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia. Semin Oncol. 2006; 33: S15-22
|
|
|
|
|
|
16) Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000; 96: 2419-25
|
|
|
|
|
|
17) Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002; 99: 1071-8
|
|
|
|
|
|
18) Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008; 359: 1786-801
|
|
|
|
|
|
19) Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med. 1998; 338: 161-5
|
|
|
|
|
|
20) Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatment for noninfectious uveitis: a multicenter noncomparative interventional case series. Opthalmology. 2005; 112: 764-70
|
|
|
|
|
|
21) Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A. 2004; 101: 8705-8
|
|
|
|
|
|
22) Rose JW, Watt HE, White AT, et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol. 2004; 56: 864-7
|
|
|
|
|
|
23) Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. 2007; 69: 785-9
|
|
|
|
|
|
24) Oh U, Blevins G, Griffith C, Richert N, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol. 2009; 66: 471-9
|
|
|
|
|